Why the study?
Do newer TKIs increase the risk of cardiovascular and arteriothrombotic adverse events compared to imatinib in chronic-phase CML patients?
Do newer TKIs increase the risk of cardiovascular and arteriothrombotic adverse events compared to imatinib in chronic-phase CML patients?
Answers are grounded in this paper and cite their sources.
Newer TKIs, especially ponatinib, are associated with a significantly increased risk of cardiovascular and arteriothrombotic adverse events compared to imatinib in patients with chronic-phase CML, necessitating close vascular monitoring.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: